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Background: Cancer is the leading cause of disease-related death in adolescents and young adults (AYA). Annual
improvements in AYA cancer survival have been inferior to those observed in children and older adults. Prior
studies of AYA with cancer have been limited by their focus on patients from select treatment centres, reducing
generalizability, or by being population-based but lacking diagnostic and treatment details. There is a critical need
to conduct population-based studies that capture detailed patient, disease, treatment and system-level data on all
AYA regardless of treatment location.
Methods/Design: We will create a cohort of all AYA (aged 15–21 years) at the time of diagnosis with any
malignancy between 1992 and 2011 in Ontario, Canada (n = 5,394). Subjects will be identified through the Ontario
Cancer Registry and the final cohort will be expanded to include 2012 diagnoses, as these data become available.
Detailed diagnostic, treatment and outcome data for those patients treated at a pediatric cancer centre will be
provided by a population-based pediatric cancer registry (n = 1,030). For 15–18 year olds treated at adult centres
(n = 923) and all 19–21 year olds (n = 3396), trained abstractors will collect the comparable data elements from
medical records. We will link these data to population-based administrative health data that include physician
billings, hospitalizations and emergency room visits. This will allow descriptions of health care access and use prior
to cancer diagnosis, and during and after treatment.
Discussion: The IMPACT cohort will serve as a platform for addressing questions that span the AYA cancer journey.
These will include determining which factors influence where AYA receive care, the impact of locus of care on the
types and intensity of cancer therapy, appropriateness of surveillance for disease recurrence, access to clinical trials,
and receipt of palliative and survivor care. Findings using the IMPACT cohort have the potential to lead to changes
in practice and cancer policy, reduce mortality, and improve quality of life for AYA with cancer. The IMPACT data
platform will be a permanent resource, accessible to researchers across Canada.
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Over 2,300 Canadians aged 15–29 years develop cancer
annually [1]. Cancer is the leading cause of disease-
related death in adolescents and young adults (AYA)
[2-5], yet improvements in survival and focused research
lag behind that in children and older adults. Over the
past 25 years, annual improvement in 5-year cancer sur-
vival has exceeded 1.5% in both children <15 years and
adults >50 years [6]. In contrast, the annual improve-
ment in survival has been less than 0.5% in 15–24 year
olds and non-existent in those aged 25–29 [3,6-8]. The
reasons for the disparities are unclear, but likely include
patient, disease, and health care system factors including
unfavorable tumour biology [9,10], increased risk for
acute toxicity from therapy [11-14], poor adherence to
therapy [15], vulnerability to diagnostic delay [16-18]
resulting in advanced stage at diagnosis [18,19] and limi-
ted opportunities to participate in clinical trials [6,20].
Location of cancer therapy may exacerbate or mitigate
the above vulnerabilities. In Ontario, 19% of 15–21 year
olds are treated at a pediatric cancer centre, 57% at an
adult Regional Cancer Centre (RCC), and 24% at a com-
munity hospital (unpublished data). Most care settings
do not have specific programs focused on addressing the
differences in disease biology and response to therapy
[20-22] or the risks for toxicity and late effects of the-
rapy including infertility [23-25] cardiac, pulmonary or
other treatment repercussions [26-28], secondary malig-
nancies [29,30], as well as the unique health and psycho-
social issues faced by AYA, such as difficulty reentering
school or the workforce, and forming or maintaining ro-
mantic relationships [31-33]. Despite recommendations
that AYA cancer therapy be administered by experts in
AYA oncology [34], AYA comprise a small percentage of
patients seen in either pediatric or adult centres [2,34].
This results in a paucity of AYA expertise, which may
lead to variations in care and treatment intensity bet-
ween sites. AYA who receive their therapy in a com-
munity hospital are particularly vulnerable; in a recent
analysis of Ontario AYA with lymphoma, we demon-
strated that those patients who were treated in a cancer
centre (pediatric or adult) had a 16% higher likelihood of
survival than those treated in a community hospital [35].
Disparities in outcome by LOC have been observed in
leukemia, sarcoma, non-Hodgkin lymphoma (NHL) and
brain tumours [36-40].
Disparities in AYA cancer care and outcomes extend
beyond survival to encompass end-of-life and survivor
care. Studies of survivors of childhood cancer (including
some AYA) have found that the majority will develop
late effects of therapy that are often severe and can lead
to premature death [41-44]. Since adolescence and young
adulthood is a period of substantial physical and emo-
tional development, AYA may be particularly vulnerableto these late effects. Variations in care according to LOC
may impact outcomes in AYA cancer survivors. For ex-
ample, treatment of Hodgkin’s Lymphoma with adult-type
anthracycline-based therapy increases the risk for cardiac
disease, while pediatric regimens that contain alkylating
agents may have greater impact on fertility [45-47].
Although LOC likely impacts cancer survival, risk for
late effects, and access to palliative and survivor care, lit-
tle is known about determinants of LOC in AYA. A US
study found that younger age and cancer type influenced
the chance of AYA being referred to a pediatric centre
[48]. Cancers such as ALL were more likely to be treated
in a pediatric centre; thyroid and other carcinomas were
more frequently treated at an adult centre. An AYA’s pri-
mary care practitioner’s (PCP) specialty likely influences
referral patterns, but this variable has not been studied.
The patient, disease and system factors that determine
LOC in Canada’s universal health care system have not
been examined.
Here we report on the design and methods of the
Initiative to Maximize Progress in AYA Cancer Therapy
(IMPACT) Study. This is the first population-based cohort
study of all AYA aged 15–21 with complete diagnostic,
treatment, and outcomes data. The IMPACT study will
address several gaps in the literature. We aim to:
1. Determine patient and healthcare system factors
that determine LOC;
2. Identify whether LOC is associated with variation in
care across the cancer continuum, including
intensity and type of cancer therapy, clinical trial
enrollment, guideline-recommended survivor care
and end-of-life palliation;
3. Examine the relationship between LOC and survival
within malignancy groups accounting for potential
confounders (patient demographics, stage at
diagnosis, disease biology). For those malignancies in
which overall or event-free survival differs by LOC,




This study will include 5,349 AYA aged 15–21 years
diagnosed with any malignancy in the Ontario from
1992–2011 (Figure 1). The cohort will be identified
through the Ontario Cancer Registry (OCR) and expanded
to include diagnoses in 2012, as these data become avail-
able. The OCR, operated by Cancer Care Ontario, cap-
tures information on all incident cancers in Ontario since
1964 and is over 95% complete [49]. Data on disease
characteristics, treatment and outcomes will be collected
using linkage to the Pediatric Oncology Group of Ontario
Networked Information System (POGONIS) for patients
AYA aged 15-21 diagnosed with 









Figure 1 Eligibility for the IMPACT cohort.
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for patients treated elsewhere. The number of included
AYA by LOC for common malignancies is estimated in
Table 1. Linking this cohort to health services and other
population-based databases housed at the Institute for
Clinical Evaluative Sciences (ICES) will enable collection
of data regarding demographics, healthcare utilization
before, during and after treatment, and key short- and
long-term outcomes (Figure 2). These databases are not
publicly accessible. Permission was granted to access
POGONIS by the Pediatric Oncology Group of Ontario
and remaining databases are accessible upon approval of
the privacy office at ICES. ICES and POGO are named
prescribed entities under section 45(1) of Ontario’s Per-
sonal Health Information Protection Act (PHIPA, 2004).
This permits health information custodians (such as
hospitals) to disclose PHI to these agencies “for the pur-
pose of analyzing and/or compiling statistical information
with respect to the management of, evaluation or moni-
toring of, the allocation of resources to or planning for all
or part of the health system, including the delivery of
services” without individual consent. The Research EthicsTable 1 Distribution of locus of care for the most common ad
Ontario, Canada
Malignancy type N Pedia
Hodgkin lymphoma 986 238 (2
Thyroid cancer 677 34 (5.
Bone/soft tissue sarcomas 545 152 (2
Testicular cancer 507 30 (6.
Leukemia 483 184 (3
Brain tumours 482 172 (2
Non-Hodgkin lymphoma 421 109 (2
Other 1248 241 (1
Total 5349
Abbreviation: RCC, Regional Cancer Centre.Board at St. Michael’s Hospital, Toronto, Canada has
approved the protocol for this study (12–233).
Disease and treatment data
POGONIS
Launched in 1985, POGONIS collects detailed demo-
graphic, disease, treatment and outcome data on all pa-
tients with a malignancy treated at any of Ontario’s five
pediatric cancer centres. Trained data managers collect
data prospectively. Data on 1,030 cohort members treated
at a pediatric centre will be provided by POGONIS.
Chart abstraction
No comparable registry exists for AYA treated at adult
centres. Clinical data for 4,319 AYA will be obtained
through chart abstraction. Trained abstractors with ex-
tensive experience in cancer studies will abstract vari-
ables through review of hospital and pharmacy records,
radiation planning records, operative and pathology
reports, and discharge summaries. Abstractors will work
on-site using ICES-developed software that allows entry
of personal health information onto encrypted laptops.
Abstractors have already received extensive training
from the study team including in-depth review of ab-
straction manuals and mock chart abstraction. A robust
protocol for real-time data review will ensure quality
abstraction: abstractors will have timely access to study
team members for content-related questions. Investi-
gators will review summaries of abstracted charts on a
regular basis to ensure data validity, completeness and
consistency between abstractors.
Data variables
Malignancy-level data will include histology, stage, pri-
mary tumour site, laterality, metastatic sites, diagnostic
method, and disease status (relapse, progression)
(Table 2). We will classify disease using the Internationalolescent and young adult malignancies, ages 15–21, in
Adult n (%)
tric n (%) RCC Community
4.1) 710 (72.0) 38 (3.9)
1) 227(33.5) 415 (61.4)
7.9) 273 (50.1) 120 (22.0)
0) 422 (83.3) 54 (10.7)
8.0) 255 (52.7) 45 (9.3)
5.7) 221 (45.8) 89 (18.5)
5.8) 212 (50.4) 100 (23.8)






















Figure 2 Primary data on members of IMPACT cohort will be linked to multiple administrative datasets held at the Institute for Clinical
Evaluative Sciences to create a comprehensive cohort of all AYA in Ontario including demographic, diagnosis, treatment, recurrence,
outcomes and health services use information. Abbreviation: POGONIS, Pediatric Oncology Group of Ontario Networked Information System.
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International Classification of Disease-O systems, allowing
comparison of patients treated as these classification sys-
tems evolved. Pathology and cytogenetic reports are being
scanned to facilitate centralized verification of findings.
Total dose (per m2) will be calculated for chemotherapies
most associated with late effects (e.g. anthracyclines,
alkylating agents). Information about clinical trial enroll-
ment and treatment protocols will enable evaluation of
the impact of trial enrollment or treatment according to
published protocols on survival.
Health services and demographic data
Health services data
The cohort will be linked to administrative databases
maintained at ICES using a patient-specific encrypted
identifier. The Canadian Institute for Health Information
(CIHI) Discharge Abstract Database (DAD) contains one
record for each hospital stay in Ontario since 1988.
The CIHI National Ambulatory Care Reporting System
(NACRS) captures information on outpatient visits to hos-
pitals and community-based ambulatory care since 2002.
The Home Care Database captures all services provided or
coordinated by Ontario’s Community Care Access Centres
since 2005. Ontario Health Insurance Plan (OHIP)
data contains inpatient and outpatient service claims and
procedure billing information paid to physicians, groups,
laboratories, and out-of-province providers; healthcare
utilization before, during and after treatment can therefore
be assessed. Characteristics of physicians involved in the
care of cohort members will be determined through the
ICES Physicians Database, which includes information
on physician specialty, demographics, practice type and
location.Patient demographics
These data will be obtained from the Registered Persons
Database (RPDB), a vital statistics registry created in
1990 comprised of all individuals who have ever been
insured to receive a health service in Ontario. Postal
code at diagnosis will be used to determine geographic
location (to calculate the shortest distance to a cancer
centre), rurality and socioeconomic status (SES) by link-
age to census data on median neighbourhood household
income (an ecologic measure of SES routinely used in
Canadian research).Outcome data
Fact of and cause of death will be identified by linkage
to the RPDB, and subsequent malignancies will be iden-
tified by linkage to the OCR. Both death and subsequent
malignancies will be confirmed by chart abstraction
using the same methods as the primary malignancy.Locus of care
LOC will be categorized into three broad groups based
on the primary location of cancer treatment: pediatric
centre, RCC, or community hospital. In some circum-
stances, AYA receive elements of care in different cen-
tres. We will define the site of cancer-directed surgery,
chemotherapy, radiation and stem cell transplantation
for each patient. For AYA who received chemotherapy,
LOC will be designated as the site at which the chemo-
therapy was administered, regardless of other therapies
received. For those treated with cancer-directed surgery
with and without radiation (but without chemotherapy),
LOC will be considered the site of surgery. For evaluation
of specific treatments (e.g. intensity of chemotherapy, type
Table 2 Selection of data elements contained in POGONIS
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Second malignant neoplasms (date/site)
Death/last follow up (date, location, cause
of death)
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location of the specific treatment.
Because surveillance for late effects and palliative care
occur after diagnosis, we will redefine LOC for these
outcomes. We will determine survivors’ patterns of visits
and classify follow-up care in each year hierarchically as
cancer-centre/oncologist-based, primary care based, or
none.
Aim 1: To determine the patient and healthcare system
factors that determine LOC
We will evaluate the relationship between LOC and type
of PCP, distance from RCC and SES.
Potential explanatory variables
Patients will be designated as having a pediatrician, a fam-
ily physician/general practitioner or no PCP in the 2 years
prior to diagnosis based on pre-diagnosis healthcare bil-
lings. Postal code at diagnosis will be used to geocode pa-
tients, hospitals and cancer centres to a geographic point
on a spatial areal map. For each AYA, the straight-line
distance to the nearest pediatric centre or RCC during the
year of the cancer diagnosis will be calculated using
a Statistics Canada algorithm [50,51]. We will use the
straight-line distance as a proxy for actual travel burden
[52]. SES will be determined by linkage to census data on
median neighbourhood household income.
Data analysis
We will generate descriptive statistics overall, by PCP type,
SES and geographic distance from a pediatric centre or
RCC. We will create a multivariate multinomial logistic
regression model with PCP type, geographic distance and
SES quintile as independent variables, and LOC as the
dependent variable. As distance will be positively skewed,
we will evaluate the impact of distance as a continuous
variable and as a categorical variable in 25 km increments.
We will use a general estimating equations approach to
adjust for clustering at the PCP level. We will test for
interactions between PCP type, geographic distance and
SES, and between time period and geographic distance. Of
note, we may find patients living far from any treating
institution have different patterns of referral than those
living closer. To evaluate this, we will identify patients
living in communities considered both Northern and
Rural by the Ontario Ministry of Health and Long Term
Care [53] and will create a separate geographic category
for these geographically isolated patients.
Aim 2: To evaluate the relationship between LOC and
AYA care across the cancer continuum
We will evaluate the influence of LOC at three distinct
points on the cancer continuum: 1) during active cancer
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active treatment; and 3) at end-of-life (if applicable).
Cancer therapy
We will limit this analysis to patients undergoing treat-
ment with curative intent, as determined by chart review.
Clinical trial enrollment (yes/no) and protocol name will
be abstracted. Treatment intensity (chemotherapy, radia-
tion therapy and surgery) will be defined from chart re-
view data for specific malignancies (Table 2). For example,
we will evaluate the length of primary therapy, cumulative
dose of anthracyclines and use of cranial radiation therapy
in patients with acute lymphoblastic leukemia, and the
dose and fields of radiation and doses of anthracyclines
and alkylating agents in patients with HL.
Risk-based survivor care
Based on chart review data, cohort members in remis-
sion ≥5 years from diagnosis will be designated as survi-
vors. Using the Children’s Oncology Group guidelines
[54], we will identify those survivors at high risk for car-
diac dysfunction, secondary breast cancer and colorectal
cancer (late effects that cause morbidity and potential
mortality, have established surveillance protocols, and
are reliably detected using administrative data) (Table 3).
Using OHIP billing codes, we will determine adherence
to recommended surveillance over time.
End-of-life palliation
For this analysis, the study population will consist of
cohort members who died after experiencing relapse or
progression, thereby excluding deaths related to toxicity
of initial cancer therapy. Access to formal palliative care
services will be determined through inpatient and out-
patient palliative care claims.
Data analysis
A variety of statistical methods will be used. Multivari-
able logistic regression modeling will be implemented to
examine factors associated with being enrolled on a
clinical trial and intensity of cancer therapies. The main
exposure will be LOC and the model will be adjusted
for demographic, disease, and provider characteristics. ATable 3 Definition of risk and required surveillance in survivo
Breast cancer Col
Definition of high risk
group






for survivors at high risk
Annual mammogram/MRI beginning
8 years after radiation or age 25 years,
whichever occurs last
Col
beggeneralized estimating equations approach [55] will be
used to account for clustering of patients within indi-
vidual centres. Relationships between covariates will be
explored using the variance influence factor to ensure
that highly correlated variables are not included together
in multivariable regression models. If two variables are
highly correlated, we will include the variable that is
deemed most clinically relevant to the outcome.
To evaluate repeated events (e.g. risk-based survivor
care), we will examine the relationship of LOC with
breast imaging, echocardiogram/MUGA, and colorectal
cancer screening in those survivors at high risk for
specific late effects. The timing of these repeated events
varies depending on the care recommended in the guide-
lines. Using a counting process model (based on a Poisson
process) [56], the rate of event occurrence for each patient
will be modeled as a function of time, and available
covariates. The model will incorporate fixed and time-
dependent covariates (LOC for follow-up care may change
yearly). Likelihood-based methods will be used to estimate
the regression parameters [57].
We will use time to event methods to evaluate the
relationship between LOC and end-of-life palliative care.
Timing of palliative care in relation to major events
(diagnosis, relapse/progression, death) will be described.
Cox proportional hazards regression will model the
association of LOC with time to palliative care involve-
ment, using the first relapse/progression as time zero.
Subsequent relapses/progressions will be treated as
time-varying covariates. Variable interactions with time
period will be explored.
Given our robust chart review process, and because
most outcomes will be determined through linkage to
administrative data, we expect few data to be missing.
However, to handle missing data for a specific variable,
we will first assess whether the data are missing com-
pletely at random (MCAR), missing at random, or mis-
sing not at random [58]. If the data are MCAR, then we
will proceed with complete case analysis. Although there
is a loss of power with this approach, the estimated re-
gression parameters are not biased by the absence of the
data. When data are not MCAR, multiple imputation
methods will be implemented; these techniques producers at HIGH risk of a late effect
orectal cancer Cardiomyopathy
Gy radiation therapy
he abdomen, pelvis or spine
Anthracycline +/− chest radiation
onoscopy every 5 years
inning at age 35 years
Echocardiogram or MUGA
Annually if anthracycline ≥300 mg/m2
q 2 years if anthracycline 200–300 mg/m2
OR anthracycline <300 mg/m2 + radiation
q 5 years if anthracycline <200 mg/m2,
no radiation
Baxter et al. BMC Cancer 2014, 14:805 Page 7 of 11
http://www.biomedcentral.com/1471-2407/14/805unbiased parameter estimates and provide adequate
results in the presence of low sample size or high rates
of missing data [58].
Aim 3: To examine the relationship between LOC and
survival within malignancy groups accounting for
potential confounders
We will evaluate overall (OS) and event-free survival
(EFS) by LOC for a variety of tumor groups including,
leukemia, NHL, soft tissue/bone sarcomas and brain
tumours.
Treatment
Chemotherapy intensity will be assessed by examining
four categorical scores, one for each of alkylating agents,
anthracyclines, epipodophyllotoxins and platinum agents.
For anthracyclines, all cumulative does will be converted
to doxorubicin equivalents. Similarly, alkylating agents will
converted to cyclophosphamide equivalent doses [59].
Radiotherapy will be assessed by a yes/no categorical vari-
able along with summarized information of the total dose
received for each anatomical field. Hematopoietic stem
cell transplant will be assessed by a 4-level catego-
rical variable (0 = no transplant, 1 = autologous transplant,
2 = allogeneic transplant, related donor and 3 = allogeneic
transplant, un-related donor). Surgery will be assessed by
a yes/no categorical variable along with summarized infor-
mation of the extent of resection. We will also document
the duration of the primary therapy. Some treatment mo-
dalities will not be applicable to all diagnostic groups.
Clinical trial enrollment will be included as a dichotomous
variable.
Covariates
Age (by year, and categorized as adolescent vs. adult), sex
(when applicable) and SES (quintiles) will be determined
from the RPBD. Other disease factors such as stage, grade
and molecular markers will be included were appropriate
(e.g. Philadelphia chromosome in ALL).
Data analysis
We will report crude rates of OS and EFS for the entire
cohort and for each disease group, by LOC. To study
OS, standard techniques for survival analysis will be
applied. For each malignancy group, the Kaplan-Meier
approach will be used to obtain a non-parametric esti-
mate of the survivor function for each LOC, separately.
The Nelson-Aalen approach will be used to provide
nonparametric estimates of the cumulative hazard func-
tions. Similar techniques will be applied to study EFS.
To model OS for the entire cohort and for each malig-
nancy, we will use a Cox proportional hazards regression
approach to examine the relationship between OS and
pre-specified covariates of key interest (above). Multipleother variables that may influence cancer survival will be
available through chart review and administrative data;
analyses that include these factors will be considered ex-
ploratory. We will conduct several tests, including exa-
mining residual plots, to ensure the proportional hazards
assumption is appropriate. If violated, we will expand the
model by exploring various interactions between time and
the covariate in question. Centre-specific random effects
[60] will be incorporated into Cox regression models to
account for correlation that may arise due to clustering of
patients within centres. To model EFS for the entire co-
hort and for each malignancy, we will use similar tech-
niques as discussed for OS. Missing data will be treated as
described in Aim 2.
Our cohort spans diagnoses identified over a 20-year
period. As such, cohort effects would normally be consid-
ered in the analysis phase. Previous work examining the
effect of LOC has indeed used period of diagnosis as a
prognostic factor and in all studies, it was used as a proxy
for differences in diagnostic techniques and treatment
approach. Given that the central aim of our analysis is to
examine differences in diagnosis and treatment, and that
we will have collected detailed data on all treatment
exposures, period of diagnosis will not be relied upon as a
proxy for these exposures.
Sample size and power considerations
We have provided power calculations for selected hy-
potheses across aims 1–3. These hypotheses were se-
lected to highlight power sufficiency even for hypotheses
with limited sample sizes.
Aim 1
To assess the hypothesis that increasing distance from a
pediatric centre or RCC will be associated with a lower
likelihood of referral to a cancer centre (pediatric centre
or RCC) versus a community hospital, the total cohort
of 5,349 patients will utilized. It is estimated that ap-
proximately two thirds live less than 50 km away from a
cancer centre. Assuming that the average probability of
attending a cancer centre is 76% (4,065/5,349), there will
be 80% power to detect at least a 4% absolute difference
in probability of attending a cancer centre between pa-
tients living less than 50 km away from a cancer centre
vs. those living greater than 50 km away. These calcula-
tions use a two-sided binomial test with alpha of 0.05.
Aim 2
We present the power to demonstrate important dif-
ferences in clinical trial enrollment and palliative care.
Of the 5,349 patients in our cohort, 1,030 patients
attended a pediatric centre and 3,035 patients attended a
RCC. From POGONIS, we know that the average prob-
ability of being enrolled on a clinical trial among those
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there will be 80% power to detect at least a 5.1% abso-
lute difference in trial enrollment rates between patients
attending a pediatric centre and those attending a RCC.
These calculations use a two-sided binomial test with
alpha of 0.05.To assess the hypothesis that end-of-life
care is associated with LOC, we will only examine
disease-related deaths. Of the 931 deaths identified in
our cohort, we estimate that 740 (80%) are disease-
related. We estimate that approximately one third of pa-
tients dying of cancer will receive palliative care. We also
estimate that 584 of the 740 patients will have been
treated in a cancer centre (pediatric or RCC) at the time
of their last cancer treatment and 156 at community
hospitals. Assuming that 60% of terminal AYA treated at
a cancer centre receive palliative care services within
2 months of their death, we will have 80% power to
detect at least a 35% higher rate of receiving palliative
care among patients in cancer centres versus patients in
community hospitals. These calculations are based on
the log rank test, type I error alpha 0.05.
Aim 3
Survival probabilities for patients treated in a pediatric
centre have been provided by the Pediatric Oncology
Group of Ontario. For sarcomas (152 pediatric; 273
RCC), based on a 5-year mortality rate of 32% in a
pediatric centre, we will have 80% power to detect at
least a 44% increase in hazard of death for patients
treated in an RCC vs. pediatric centre. For leukemia
(184 pediatric; 255 RCC), based on a 5-year mortality
rate of 21% among patients treated in a pediatric centre,
we will have 80% power to detect at least a 49% increase
in hazard of death for patients treated in an RCC vs.
pediatric centre. For brain tumours (172 pediatric; 221
RCC), based on a 5-year mortality rate of 31% among
patients treated in a pediatric centre, we will have 80%
power to detect at least a 46% increase in hazard of
death for patients treated in a RCC vs. pediatric centre.
For NHL (109 pediatric; 212 RCC), based on a 5-year
mortality rate of 25% among patients treated in a
pediatric centre, we will have 80% power to detect at
least a 59% increase in hazard of death for patients
treated in a RCC vs. pediatric centre. The power calcula-
tion uses a log rank test with type I error alpha of 0.05.
Discussion
Cancer is the leading cause of disease-related death in
AYA, yet healthcare systems frequently fail to meet the
needs of this vulnerable group [21]. Critical outcomes
such as improvement in survival over time and access to
supportive care have not kept pace with those in chil-
dren or the elderly. Given the many life years impacted
by a cancer diagnosis for AYA, these deficiencies in caremust be addressed. AYA aged 15–21 may be treated in a
specialized pediatric oncology unit within a pediatric
centre, at an RCC, or a community hospital. Conse-
quently, these young people are most likely to benefit
from research exploring the relationship between LOC
and the types and intensity of treatment, access to clin-
ical trials, palliative and survivor care, and most impor-
tantly, their chance of survival. An increased focus by
government and the cancer community [61-65] on dis-
parities in AYA cancer care has created an opportunity
to effect change in provincial and national cancer policy
that will determine where AYA are treated and what
medical and supportive care resources are essential to
optimize care. Cancer Care Ontario and other provincial
cancer agencies have launched initiatives to create spe-
cialized “Service Provider Sites” for individual malig-
nancy groups (e.g. sarcoma) to ensure equitable access
to high quality cancer services with integrated, multi-
disciplinary expertise. Provider sites will be concentrated
in a limited number of institutions to ensure sufficient
volume to maintain expertise. Our analysis will inform
similar initiatives focused on ensuring that AYA can
access quality cancer care.
Beyond influencing policy regarding the optimal LOC
for AYA that will ensure equal opportunity for survival,
the work performed using this cohort will impact the
care of AYA with terminal cancer and those who be-
come long-term survivors. Data regarding access to ap-
propriate palliative care for AYA is sparse. This study
will provide foundational information by identifying fac-
tors that impede prompt AYA access to palliative care. It
will inform targeted policies to ensure all AYA with ter-
minal cancer receive early and appropriate palliative care
(such as immediate introduction of palliative care to
at-risk subgroups). It will also aid in efforts advocating
for novel programs and technologies with the potential
to improve end-of-life AYA care [66-68]. This analysis
will inform potential strategies to improve AYA survivor
care: the creation of dedicated AYA survivor programs
in a limited number of centres, expansion of existing
programs for pediatric cancer survivors, or education
initiatives to improve survivor and PCP knowledge and
compliance with surveillance guidelines.
Beyond its impact on guiding policy, the IMPACT
cohort will provide an unparalleled resource for future
research. The IMPACT data platform will be established
as a permanent resource enabling other investigators
with an interest in AYA cancer to perform their own in-
vestigation into AYA cancer. The level of detail available
in the database and via linkage to ICES’ other data hol-
dings will create numerous opportunities to complete
studies that address a range of issues that span the AYA
cancer journey and have the potential to improve both
the quantity and quality of AYA cancer survival.
Baxter et al. BMC Cancer 2014, 14:805 Page 9 of 11
http://www.biomedcentral.com/1471-2407/14/805Abbreviations
ALL: Acute lymphoblastic leukemia; AYA: Adolescent and young adults;
CIHI: Canadian Institutes of Health Information; DAD: Discharge abstract
database; EFS: Event-free survival; GEE: Generalized estimating equations;
HL: Hodgkin’s lymphoma; ICES: Institute for Clinical Evaluative Sciences;
IPDB: ICES physicians database; LOC: Locus of Care; MCAR: Missing
completely at random; NACRS: National Ambulatory Care Reporting System;
NHL: Non-Hodgkin’s lymphoma; PCP: Primary care practitioner; RCC: Regional
cancer centre; RPDB: Registered persons database; OCR: Ontario Caner
Registry; OHIP: Ontario Health Insurance Plan; OS: Overall survival;
POGONIS: Pediatric Oncology Group of Ontario Networked Information
System; SES: Socioeconomic status.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NB and PN conceived the study, developed the study methods, are
responsible for the integrity of primary data collected, and drafted the
manuscript. CD is responsible for coordination of data abstraction and
overall study management, and edited the manuscript. SG conceptualized
palliative care outcomes and edited the manuscript. JP is responsible for
data linkage, statistical analysis and edited the manuscript. MG provided
expertise on study methods and outcome measures and edited the
manuscript. RS was responsible for the development of statistical analysis
plan and edited the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This research study is being conducted with support from the C17 (partially
funded by Childhood Cancer Canada Foundation and the Kids With Cancer
Society), the Pediatric Oncology Group of Ontario Research Unit, the
Canadian Institutes of Health Research (CIHR, 133618) and a Health Services
Research Chair awarded to Dr. Nancy Baxter.
This study is supported by the Institute for Clinical Evaluative Sciences (ICES),
which is funded by an annual grant from the Ontario Ministry of Health and
Long-Term Care (MOHLTC). The opinions, results and conclusions reported in
this paper are those of the authors and are independent from the funding
sources. No endorsement by ICES or the Ontario MOHLTC is intended or
should be inferred.
Author details
1Department of Surgery, St. Michael’s Hospital, 30 Bond Street, Toronto, ON
M5B 1W8, Canada. 2Kennan Research Centre, St. Michael’s Hospital, Toronto,
Canada. 3Institute for Clinical Evaluative Sciences, Toronto, Canada. 4Institute
of Health Policy, Management and Evaluation, University of Toronto, Toronto,
Canada. 5The Hospital for Sick Children, Toronto, Canada. 6Dalla Lana School
of Public Health, University of Toronto, Toronto, Canada. 7Pediatric Oncology
Group of Ontario, Toronto, Canada.
Received: 2 May 2014 Accepted: 21 October 2014
Published: 3 November 2014
References
1. Canadian Cancer Society's Advisory Committee on Cancer Statistics:
Canadian Cancer Statistics 2013. Toronto, ON: Canadian Cancer Society;
2013.
2. Bleyer A, Barr R: Cancer in young adults: 20 to 39 years of age: Overview.
Semin Oncol 2009, 36(3):194–206.
3. Bleyer WA, O'Leary M, Barr R, Ries LAG: Cancer epidemiology in older
adolescents and young adults 15 to 29 y ears of age, including SEER incidence
and survival, 1975–2000. Bethesda, MD: National Cancer Institute; 2006.
4. Leading Causes of Death in Canada. 2009, [www.statcan.gc.ca/pub/84-
215-x/2012001/tbl/T003-eng.pdf]
5. Statistics Canada. [http://www5.statcan.gc.ca/cansim/a26;jsessionid=
38715DC084C7190FDAD568EF306A6807]
6. Bleyer A, Budd T, Montello M: Adolescents and young adults with cancer:
the scope of the problem and criticality of clinical trials. Cancer 2006,
107(7 Suppl):1645–1655.7. Ellison LF, Pogany L, Mery LS: Childhood and adolescent cancer survival: a
period analysis of data from the Canadian Cancer Registry. Eur J Cancer
2007, 43:1967–1975.
8. Smith MA, Seibel NL, Altekruse SF, Ries LAG, Melbert DL, O'Leary M, Smith
FO, Reaman GH: Outcomes for children and adolescents with cancer:
challenges for the twenty-first century. J Clin Oncol 2010, 28:2625–2634.
9. McNeer JL, Raetz EA: Acute lymphoblastic leukemia in young adults:
which treatment? Curr Opin Oncol 2012, 24(5):487–494.
10. Bisogno G, Compostella A, Ferrari A, Pastore G, Cecchetto G, Garaventa A,
Indolfi P, De Sio L, Carli M: Rhabdomyosarcoma in adolescents: a report
from teh AIEOP Soft Tissue Sarcoma Committee. Cancer 2012,
118(3):821–827.
11. Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, Indelicato DJ,
Hawkins DS: Patterns of chemotherapy-induced toxicities in younger
children and adolescents with rhabdomyosarcoma: a report from the
Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer 2012,
118(4):1130–1137.
12. Patel B, Richards SM, Rowe JM, Goldstone AH, Fielding AK: High incidence
of avascular necrosis in adolescents with acute lymphoblastic leukaemia:
a UKALL XII analysis. Leukemia 2008, 22:308–12.
13. Gupta A: Patterns of toxicities and outcome in children versus
adolescents/young adults (AYA) with metastatic rhabdomyosarcoma
(RMS): a report from the Children's Oncology Group (COG) Soft Tissue
Sarcoma Committee. Am Soc Clin Oncol 2013, 31:suppl; abstr 10554.
14. Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, Lange BJ,
Meshinchi S, Woods WG, Perentesis J, Horan J: Differences in outcomes of
newly diagnosed acute myeloid leukemia for adolescent/young adult
and younger patients: a report from the Children's Oncology Group.
Cancer 2013, 119(23):4162–4169.
15. Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR,
Hanby CL, Leisenring W, Yasui Y, Kornegay NM, Mascarenhas L, Ritchey AK,
Casillas JN, Dickens DS, Meza J, Carroll WL, Relling MV, Wong FL:
Nonadherence to oral mercaptopurine and risk of relapse in Hispanic
and non-Hispanic white children with acute lymphoblastic leukemia:
a report from the children's oncology group. J Clin Oncol 2012,
30(17):2094–2101.
16. Lethaby CD, Picton S, Kinsey SE, Phillips R, van Laar M, Feltblower RG: A
systematic review of time to diagnosis in children and young adults
with cancer. Arch Dis Child 2013, 98(5):349–355.
17. Dang-Tan T, Trottier H, Mery LS, Morrison HI, Barr RD, Greenberg ML, Franco
EL: Delays in diagnosis and treatment among children and adolescents
with cancer in Canada. Pediatr Blood Cancer 2008, 51(4):468–474.
18. Brasme JF, Morfouace M, Grill J, Martinot A, Amalberti R, Bons-Letouzey C,
Chalumeau M: Delays in diagnosis of paediatric cancers: a systematic
review and comparison with expert testimony in lawsuits. Lancet Oncol
2012, 13(10):e445–459.
19. Smith EC, Ziogas A, Anton-Culver H: Association between insurance and
socioeconomic status and risk of advanced stage Hodgkin lymphoma in
adolescents and young adults. Cancer 2012, 118:6179–6187.
20. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B, Biology,
Clinical Trials Subgroups of the U. S. National Cancer Institute Progress
Review Group in Adolescent Young Adult Oncology: The distinctive
biology of cancer in adolescents and young adults. Nat Rev Cancer 2008,
8(4):288–298.
21. Bleyer A, O'Leary M, Barr R, Ries LAG (Eds): Cancer Epidemiology in Older
Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence
and Survival: 1975–2000. Bethesda, MD: National Cancer Institute, NIH Pub.
No. 06–5767; 2006.
22. Barr RD: Adolescents, young adults, and cancer–the international
challenge. Cancer 2011, 117(10 Suppl):2245–2249.
23. Blumenfeld Z: Chemotherapy and fertility. Best Pract Res Clin Obstet
Gynaecol 2012, 26(3):379–390.
24. Ruddy KJ, Partridge AH: Fertility. Cancer Treat Res 2009, 151:367–385.
25. Wallace WH, Barr RD: Fertility preservation for girls and young women
with cancer: what are the remaining challenges? Hum Reprod Update
2010, 16(6):614–616.
26. Oeffinger KC, Hudson MM: Long-term complications following childhood
and adolescent cancer: foundations for providing risk-based health care
for survivors. Cancer J Clin 2004, 54(4):208–236.
27. Nathan PC, Jovcevska V, Ness KK, Mammone D'Agostino N, Staneland P,
Urbach SL, Barron M, Barrera M, Greenberg ML: The prevalence of
Baxter et al. BMC Cancer 2014, 14:805 Page 10 of 11
http://www.biomedcentral.com/1471-2407/14/805overweight and obesity in pediatric survivors of cancer. J Pediatr 2006,
149(4):518–525.
28. Krull KR, Annett RD, Pan Z, Ness KK, Nathan PC, Srivastava DK, Stovall
M, Robison LL, Hudson MM: Neurocognitive functioning and health-
related behaviours in adult survivors of childhood cancer: a report
from the Childhood Cancer Survivor Study. Eur J Cancer 2011,
47(9):1380–1388.
29. Nathan PC, Ness KK, Mahoney MC, Li Z, Hudson MM, Ford JS, Landier W,
Stovall M, Armstrong GT, Henderson TO, Robison LL, Oeffinger KC:
Screening and surveillance for second malignant neoplasms in adult
survivors of childhood cancer: a report from the childhood cancer
survivor study. Ann Intern Med 2010, 153(7):442–451.
30. Bowers D, Nathan P, Constine L, Woodman C, Bhatia S, Keller K,
Bahore L: Systematic review of subsequent neoplasms of the central
nervous system among survivors of childhood cancer: A report from
the Second Malignant Neoplasm Task Force of the Survivorship and
Outcomes Committee of the Children's Oncology Group. Lancet Oncology
2013, 14(8):e321–e328.
31. Identifying and Addressing the Needs of Adolescents and Young Adults
with Cancer: Workshop Summary: Identifying and Addressing the
Needs of Adolescents and Young Adults with Cancer: Workshop
Summary. In A LiveStrong and Institute of Medicine Workshop.
Washington, DC: The National Academies Press; 2013.
32. Bleyer WA: Cancer in older adolescents and young adults: epidemiology,
diagnosis, treatment, survival, and importance of clinical trials. Med
Pediatr Oncol 2002, 38(1):1–10.
33. French AE, Tsangaris E, Barrera M, Guger S, Brown R, Urbach S, Stephens D,
Nathan PC: School attendance in childhood cancer survivors and their
siblings. J Pediatr 2013, 162(1):160–165.
34. De P, Ellison LF, Barr RD, Semenciw R, Marrett LD, Weir HK, Dryer D,
Grunfeld E, Steering Committee for Canadian Cancer Statistics: Canadian
adolescents and young adults with cancer: Opportunity to improve
coordination and level of care. CMAJ 2011, 183(3):E187–194.
35. Furlong W, Rae C, Greenberg ML, Barr RD: Surveillance and survival among
adolescents and young adults with cancer in Ontario, Canada. Int J Cancer
2012, 131:2660–2667.
36. Epelman S: The adolescent and young adult with cancer: state of the
art-brain tumor. Curr Oncol Rep 2013, 15(4):308–316.
37. Bleyer A: The quid pro quo of pediatric versus adult services for older
adolescent cancer patients. Pediatr Blood Cancer 2010, 54:238–241.
38. Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T, Rousselot P,
Cayuela JM, Gabert J, Fegueux N, Piguet C, Huguet-Rigal F, Berthou C,
Boiron JM, Pautas C, Michel G, Fiere D, Leverger G, Dombret H, Baruchel A:
Should adolescents with acute lymphoblastic leukemia be treated as old
children or young adults? Comparison of the French FRALLE-93 and
LALA-94 trials. J Clin Oncol 2003, 21(5):774–780.
39. Gupta AA, Pappo A, Saunders N, Hopyan S, Ferguson P, Wunder J, O'Sullivan B,
Catton C, Greenberg M, Blackstein M: Clinical outcome of children and adults
with localized Ewing sarcoma: impact of chemotherapy dose and timing of
local therapy. Cancer 2010, 116(13):3189–3194.
40. Pole JD, Alibhai SM, Ethier MC, Teuffel O, Portwine C, Zelcer S, Johnston DL,
Silva M, Alexander S, Brandwein JM, Sung L: Adolescents with acute
lymphoblastic leukemia treated at pediatric versus adult hospitals.
Ann Oncol 2013, 24(3):801–806.
41. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W,
Krull KR, Green DM, Armstrong GT, Nottage KA, Jones KE, Sklar CA,
Srivastava DK, Robison LL: Clinical ascertainment of health
outcomes among adults treated for childhood cancer. JAMA 2013,
309(22):2371–2381.
42. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows
AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL,
Leisenring W, Robison LL, Childhood Cancer Survivor S: Chronic health
conditions in adult survivors of childhood cancer. N Engl J Med 2006,
355(15):1572–1582.
43. Geenen MM, Cardous-Ubbink MC, Kremer LCM, van den Bos C, van der Pal
HJH, Heinen RC, Jaspers MWM, Koning CCE, Oldenburger F, Langeveld NE,
Hart AAM, Bakker PJM, Caron HN, van Leeuwen FE: Medical assessment of
adverse health outcomes in long-term survivors of childhood cancer.
JAMA 2007, 297(24):2705–2715.
44. Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson
MM, Sklar CA, Robison LL, Oeffinger KC: Aging and risk of severe,disabling, life-threatening, and fatal events in the childhood cancer
survivor study. J Clin Oncol 2014, 32(12):1218–1227.
45. Hodgson DC: Late effects in the era of modern therapy for Hodgkin
lymphoma. Hematology 2011, 2011(1):323–329.
46. Metzger ML, Hudson MM: Balancing efficacy and safety in the
treatment of adolescents with Hodgkin's lymphoma. J Clin Oncol
2009, 27(36):6071–6073.
47. Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA,
Goodman P, Stovall M, Robison LL, Hudson MM: Morbidity and
mortality in long-term survivors of Hodgkin lymphoma: a
report from the Childhood Cancer Survivor Study. Blood 2011,
117(6):1806–1816.
48. Albritton KH, Wiggins CH, Nelson HE, Weeks JC: Site of oncologic
specialty care for older adolescents in Utah. J Clin Oncol 2007,
25(29):4616–4621.
49. Robles SC, Marrett LD, Clarke EA, Risch HA: An application of capture-recapture
methods to the estimation of completeness of cancer registration. J Clin
Epidemiol 1988, 41(5):495–501.
50. Ng E, Wilkins R, Perras A: How far is it to the nearest hospital? Calculating
distances using the Statistics Canada Postal Code Conversion File. Health Report
1993, 5(2):179–188.
51. Ng E, Pole J, Aubin M, Wilkins R: How far to the nearest physician?
Statistics Canada 1997, 8(4):19–31.
52. Haynes R, Jones AP, Sauerzapf V, Zhao H: Validation of travel times to
hospital estimated by GIS. Int J Health Geogr 2006, 5:40.
53. Rural and Northern Health Care Framework/Plan Final Report.
[http://www.health.gov.on.ca/en/public/programs/ruralnorthern/docs/
report_rural_northern_EN.pdf]
54. Children's Oncology Group: Long-Term Follow-Up Guidelines for
Survivors of Childhood, Adolescent, and Young Adult Cancers.
Version 3.0. Arcadia, CA. Available online at www.survivorshipguidelines.org.
55. Liang K, Zeger SL: Longitudinal data analysis using generalized linear
models. Biometrika 1986, 73:13–22.
56. Andersen P, Borgan O, Gill R, Keiding N: Statistical Models Based on Counting
Processes. New York: Springer-Verlag; 1993.
57. Cook R, Lawless J: The Statistical Analysis of Recurrent Events. New York, NY:
Springer; 2007.
58. Little R: Regression with missing X’s: a review. J Am Statist Assoc 1992,
87(420):1227–1237.
59. Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava D, Leisenring
WM, Neglia JP, Sklar CA, Kaste SC, Hudson MM, Diller LR, Stovall M,
Donaldson SS, Robison LL: The cyclophosphamide equivalent dose
as an approach for quantifying alkylating agent exposure: A report
from the childhood cancer survivor study. Pediatr Blood Cancer 2013,
61(1):53–67.
60. Oakes D: Bivariate survival models induced by frailties. J Am Statist Assoc
1989, 84:487–493.
61. Rogers PC, De Pauw S, Schacter B, Barr RD: A process for change in
the care of adolescents and young adults with cancer in Canada.
"Moving to Action": The Second Canadian International Workshop.
International Perspectives on AYAO, Part 1. J Adolesc Young Adult
Oncol 2013, 2(2):72–76.
62. Fernandez C, Fraser GA, Freeman C, Grunfeld E, Gupta A, Mery LS,
De Pauw S, Schacter B: Principles and recommendations for the
provision of healthcare in Canada to adolescent and young adult-
aged cancer patients and survivors. J Adolesc Young Adult Oncol 2011,
1(1):53–59.
63. Canadian Cancer Society's Steering Committee: Canadian Cancer Statistics
2009. Special Topic: Cancer in Adolescents and Young Adults. Toronto:
Canadian Cancer Society; 2009.




65. Robison LL: Opportunities and challenges of establishing a nationwide
strategy for adolescents and young adults in Canada with cancer. Cancer
2011, 117(S10):2351–2354.
66. Bradford N, Young JL, Armfield NR, Bensink ME, Pedersen LA,
Herbert A, Smith AC: A pilot study of the effectiveness of home
teleconsultations in paediatric palliative care. J Telemed Telecare 2012,
18(8):438–442.
Baxter et al. BMC Cancer 2014, 14:805 Page 11 of 11
http://www.biomedcentral.com/1471-2407/14/80567. Spice R, Read Paul L, Biondo PD: Development of a rural palliative care
program in the Calgary Zone of Alberta Health Services. J Pain Symptom
Manage 2012, 43(5):911–924.
68. De Pauw S, Ellison LF, Barr RD, Semenciw R, Marrett LD, Weir HK, Dryer D,
Grunfeld E, Steering Committee for Canadian Cancer S: Canadian
adolescents and young adults with cancer: opportunity to improve
coordination and level of care. CMAJ 2011, 183(3):E187–194.
doi:10.1186/1471-2407-14-805
Cite this article as: Baxter et al.: The Initiative to Maximize Progress in
Adolescent and Young Adult Cancer Therapy (IMPACT) Cohort Study: a
population-based cohort of young Canadians with cancer. BMC Cancer
2014 14:805.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
